抄録

背景： 冠状動脈 動脈硬化動脈硬化は、ほとんど的心筋梗塞と多くの脳卒中の背景にある病気です。コレステロールの粒子が動脈の壁に入り込み、体がそれを掃除するために免疫細胞を送り込み、何年もかけてその堆積物が硬化してプラークになります。., 、かつては進行性の不可逆的な疾患であると考えられていたが、特定の代謝および炎症条件下では生物学的に可逆的であることが現在では認識されている。画像診断を用いた 血管内超音波検査血管内超音波（IVUS）は、冠動脈の内部に通した極小の超音波プローブを使用し、内側から血管壁を撮影する検査です。. 冠動脈IVUS コンピュータ断層撮影コンピューター断層撮影法（CT）は、さまざまな角度からX線を照射し、それを再構成して体の断面画像を作成します。. 冠動脈CT検査（CCTA）、および 冠動脈定量解析法冠動脈形態定量解析は、血管造影画像の狭窄を、目視ではなく正確に測定する方法です。. (QCA)は一貫して、攻撃的な 脂質低下脂質低下とは、食事、薬、あるいはその両方によって、血中のアポBを運ぶ有害な粒子を減らすことを意味します。. または包括的なライフスタイルの変更は、以下の測定可能な退縮を引き起こす可能性がある プラーク負荷プラーク負荷とは、単に最も状態の悪い一箇所だけでなく、動脈全体に存在するプラークの総量のことです。.. しかし、管腔面積は多くの場合、並行して拡大しない。この現象は ルーメンのパラドックスThe observation that measurable plaque regression—confirmed by reductions in atheroma volume on IVUS or CCTA—is often not accompanied by a corresponding increase in luminal diameter, because the outer arterial wall simultaneously contracts (reverse remodeling) back toward its pre-disease size.. 持久力アスリートにとって、高 冠血流予備能Coronary flow reserve compares blood flow through the heart's arteries at rest with flow when the heart is working hard. そして頑健な内皮応答性があり、このパラドックスを理解することが極めて重要である。.

コンテンツ 本レビューは、機序的、臨床的、および生理学的データを統合して考察するものである。 プラーク退縮プラークの退縮とは、プラークが単に成長が遅くなるだけでなく、既存のプラークが実際に小さくなることを意味します。. そして血管リモデリングであり、特にアスリートの心臓に焦点を当てています。薬理学的人アプローチを統合し（スタチンスタチンは、肝臓がコレステロールを作るのに使う酵素の働きを遅らせます。肝臓は血液中からより多くのコレステロールを取り除くことでこれに反応し、そこに真の利益があります。., PCSK9阻害薬A PCSK9 inhibitor is a medicine that blocks that cholesterol-destroying protein, leaving more docking ports available to clear particles from the blood., 、オメガ3療法）と、ディーン・オーニッシュらの研究に由来するホールフード植物性（WFPB）栄養戦略のエビデンスを結びつけている。本レビューではさらに、退縮と 収縮性リモデリングA paradoxical shrinkage of the external elastic membrane that can accompany plaque regression, causing the vessel wall to contract inward rather than expand outward; the result is that lumen size stays the same or even decreases even as total plaque volume falls., ハイパースター循環の血行動態への影響を探求し、マスターズアスリートにおける潜在性冠動脈疾患の新たな知見を強調している。.

まとめ： プラークプラークとは、動脈の壁の内側にコレステロール、免疫細胞、瘢痕組織、カルシウムが蓄積したものです。. 退縮は、脂質のクリアランス、線維性の安定化、および 炎症炎症は、怪我や侵入物とみなしたものに対する免疫システムの反応です。これにより腫れや熱、そして浄化細胞がもたらされます。. 内腔の大きさが変化していないように見える場合でも、改善がみられます。薬物療法によって生化学的な正常化が確実になる一方で、ホールフード・プラントベース（WFPB）の栄養療法は、 血管内皮機能血管の内側を覆う内膜が血管の緊張、炎症、血液凝固を調節する能力。健康な内視細胞は一酸化窒素を放出し、動脈をリラックスさせ、プラーク形成に対する抵抗力を保ちます。. そして血管運動能。これらが一体となって、構造的な強靭性と生理機能をもたらす。.

主なメッセージ：

1. 動脈硬化の退縮は生物学的に実在し、臨床的に測定可能です。.
2. その ルーメン内腔とは、血液が実際に流れる血管の内側の開いた通路のことです。. パラドックスは〜から生じる 逆リモデリングThe inward movement of the external elastic membrane that occurs as plaque burden decreases, returning the artery toward its original, smaller caliber rather than enlarging the lumen; it is the principal explanation for the lumen paradox., 、治療の失敗ではありません。.
3. 内皮由来の一酸化窒素による血管拡張が引き起こす可能性がある 外向きの再構築Outward remodeling (also called compensatory or positive remodeling) is the process by which an artery expands its outer diameter to accommodate growing plaque, preserving the inner lumen even as the artery wall becomes more diseased; because of this, standard tests that measure only the lumen opening can miss substantial atherosclerosis. WFPBの条件下で.
4. 持久系アスリートにとって、血管の修復と血流の最適化は、二重の治療目標である。.

背景

動脈硬化は次のようにして始まります 内皮下貯留Subendothelial retention is the process by which ApoB-containing lipoprotein particles that have crossed the endothelial barrier become electrostatically bound to proteoglycans in the arterial intima and are unable to diffuse back into the bloodstream; it is considered the non-redundant first step in atherosclerosis under the response-to-retention framework. の アポリポ蛋白アポリポ蛋白とは、血液中の脂肪を運ぶ粒子に結合しているタンパク質です。脂肪と水は混ざらないため、これらのタンパク質は脂肪が血流の中を安全に移動できるようにする包みのような役割を果たします。. Bを含む リポタンパク質リポタンパク質とは、脂肪とコレステロールを血流に乗せて運ぶ小さなカプセルのことです。脂肪は水に溶けないため、移動するにはタンパク質の包みが必要です。.. の酸化修飾 LDLLDL（低密度リポ蛋白）は、コレステロールを血液中に運ぶ主要な粒子であり、動脈壁に詰まる主原因となるものです。. 微粒子が単球接着のカスケードを引き起こす, マクロファージマクロファージは、ゴミや侵入者を飲み込む大きなどん欲な免疫細胞です。その名前は文字通り「大食い」を意味します。" 活性化、および平滑筋の遊走。数十年かけてこれは脂質に富んだ、炎症性の、そして線維性のプラークへと繋がり、動脈の弾力性を損なわせる。歴史的に、この疾患は不可逆的であると考えられており、2世紀半ばの解剖データは単調な進行を描写していた 内膜肥厚内膜肥厚は、動脈の内層（内膜）の厚さにおける初期の適応的または病的な増加であり、正常な発達的変化、あるいは明白なプラーク形成に先行する平滑筋細胞、脂質、炎症性細胞の蓄積のいずれかを反映しうる。これは、頸動脈内膜中膜複合体厚の超音波検査によって非侵襲的に測定可能である。..

しかし、脂質代謝、マクロファージ生物学、および血管イメージングにおける発見が、この宿命論を覆した。流入が 動脈硬化惹起性粒子動脈硬化惹起性粒子とは、LDL、IDL、VLDL、リポ蛋白(a)といったアポB含有リポ蛋白のことであり、動脈壁に侵入・停滞してプラークの成長を開始・持続させます。本論文では、プラークの退縮を達成するために大幅かつ持続的に低下させなければならない対象を指す言葉としてこの用語を使用しています。. 停止し炎症が収まれば、プラークは縮小して再安定化することがある。現代の見方は、損傷と修復の動的な平衡状態であるというものであり、そのプロセスは コレステロールコレステロールは、体が必要とするロウ状の物質です。細胞壁、ホルモン、ビタミンD、そして食べ物を消化する胆汁の材料となります。コレステロールがなければ私たちは生きていけません。. 輸送、内皮の完全性、および全身性炎症。.

回帰には相互に依存する3つの領域が含まれます：

• プラークの生物学 – 脂質枯渇、マクロファージ表現型スイッチング、, 細胞外マトリックスThe extracellular matrix is the scaffolding of collagen and other fibers that holds tissue together and gives an artery wall its strength. 再構築.
• 船舶改造 – 壁応力を調整する外側弾性膜の外向きまたは内向きの動き。.
• 血管運動トーンThe degree of active contraction or relaxation of smooth muscle in the arterial wall that continuously adjusts lumen diameter in response to metabolic demand, endothelial signals such as nitric oxide, and neural input; improved vasomotor tone after lifestyle intervention can widen the functional lumen even without structural plaque loss. 内皮由来の一酸化窒素依存性血管平滑筋弛緩.

イン 臨床試験臨床試験とは、研究者が一方のグループに治療法を施し、もう一方のグループにはプラセボ（偽薬）または標準治療を施して、その結果を比較する研究のことです。., 、介入は最初のドメインを改善する一方で、後の2つは変化させないか、あるいはむしろ収縮させ、ルーメンのパラドックスを引き起こすことが多い。.

回帰のメカニズム

脂質と細胞のダイナミクス

血漿LDLコレステロールが内膜停滞の閾値（約50 mg/dL）を下回ると、脂質の流入が治まる。マクロファージ 泡沫細胞A foam cell is an immune cell that has eaten so much trapped cholesterol that it swells up and looks foamy under a microscope. ATP結合カセットトランスポーターを活性化する ABCA1ABCA1は、コレステロールを細胞の外へ汲み出し、肝臓へ戻るためのHDL粒子に受け渡すタンパク質です。. そしてABCG1は、コレステロールをapoA-Iへ排出し、 HDLHDL、すなわち高密度リポタンパク質は、しばしば「善玉コレステロール」と呼ばれる粒子です。組織からコレステロールを回収し、肝臓へ運び戻します。.. コレステロールの排泄が流入を上回るにつれて、細胞内の脂質滴が溶解し、マクロファージは抗炎症性サイトカインやマトリックス成分を分泌する修復型のM2表現型へと移行する。.

炎症の収束とマトリックスリモデリング

NF-κBの活性化低下と NLRP3インフラマソームThe NLRP3 inflammasome is an intracellular protein complex in immune cells that, when activated by cholesterol crystals, oxidized lipids, or other danger signals within an atherosclerotic plaque, triggers the release of the inflammatory cytokines interleukin-1β and interleukin-6, accelerating plaque growth and instability. 経路はインターロイキン-1βおよび腫瘍壊死因子αを減少させる。. マトリックスメタロプロテイナーゼMatrix metalloproteinases are enzymes that cut through the collagen scaffolding of tissue. Immune cells inside plaques release them. （MMP）の発現が低下し、一方でマトリックスメタロプロテイナーゼ阻害物質（TIMP）が上昇するため、線維性被膜の肥厚が促進される。平滑筋細胞によるコラーゲン合成が 病変循環器学において、病変とは冠動脈を狭窄させるアテローム性動脈硬化プラークの不連続な領域を指し、通常はそれが引き起こす内腔閉塞のパーセンテージによって記述される。この記事では、最も重要な病変が治療された後、血管径が小さすぎてステントを受け入れることができない4つの遺残病変について述べている。. そして破裂を防ぐ。.

内皮の修復と一酸化窒素の生物学

内皮型一酸化窒素合成酵素（eNOS）Endothelial nitric oxide synthase is the enzyme in artery-lining cells responsible for producing nitric oxide, which relaxes blood vessels and suppresses clot formation; in insulin resistance, impaired insulin-receptor signaling downregulates eNOS, reducing nitric oxide availability and promoting an adhesive, pro-inflammatory arterial surface. 切り離し、の顕著な特徴 酸化ストレス酸化ストレスとは、有害な活性分子と、それらを中和する身体の能力との間の不均衡です。., は、テトラヒドロビオプテリンの利用可能性が改善するにつれて反転します。NOは血管拡張を回復し、血小板凝集を抑制し、減少し 白血球接着The process by which white blood cells attach to the endothelial surface of blood vessels, a key early step in atherogenesis; nitric oxide and an intact glycocalyx normally suppress this adhesion.. 運動、植物性硝酸塩、そして ポリフェノールポリフェノールは抗酸化作用を持つ植物由来の化合物の総称であり、エキストラバージンオリーブオイルにはこれが特に豊富に含まれています。ハードな心血管エンドポイントを測定した臨床試験では意味のある臨床的利益は確認されていないものの、精製オリーブオイルよりも保護効果が高い可能性がある理由として、ポリフェノールがしばしば挙げられます。. 環状GMPシグナル伝達を介してこの経路を増強する。.

酸化ストレスの制御

活性酸素種Reactive oxygen species are unstable oxygen-containing molecules produced as a by-product of normal metabolism. NADPHオキシダーゼおよびアンカップルしたeNOSによって生成される（ROS）は、加速させる アテローム発生アテローム性動脈硬化形成は、プラークが形成される段階的なプロセスです。.. 回帰には以下の活性化が伴う。 抗酸化物質抗酸化物質とは、体内にある有害な分子を取り除く物質です。ビタミンEやベータカロテンはその例です。. 転写因子Nrf2、ヘムオキシゲナーゼ-1（HO-1）の発現上昇、および低下 脂質過酸化脂質過酸化は、活性酸素種が不飽和脂肪酸の二重結合を攻撃し、潜在的に有害な酸化生成物に分解する連鎖反応です。種子油に含まれる多価不飽和脂肪は、特に熱や繰り返しの揚げ物調理によって、飽和脂肪や一価不飽和脂肪よりもこのプロセスを受けやすくなります。.. これらの変化は内皮透過性を低下させ、NOの生物学的利用能を維持する。.

内皮前駆細胞と修復

高強度スタチン高強度のスタチンとは、LDLコレステロールを50%以上減少させることが期待される投与量であり、実際にはアトルバスタチンやロスバスタチンの高用量がこれに該当する。., 有酸素運動有酸素運動は、早歩き、サイクリング、水泳、ジョギングのように、しばらくの間呼吸が激しくなるような持続的な運動のことです。., 、およびWFPB栄養学はそれぞれ動員します 内皮前駆細胞Bone-marrow-derived precursor cells that circulate in the bloodstream and home to sites of endothelial injury, where they participate in re-endothelialization and microvascular repair; their mobilization is enhanced by statins, aerobic exercise, and whole-food plant-based nutrition. 骨髄由来であり、再内皮化を促進し、微小血管の健康を改善する。.

これらのプロセスが蓄積することで、プラークは脂質に富み破裂しやすい状態から、線維化して静穏な状態へと変化します。これは、血管内腔の直径が変わらない場合であっても、動脈の真の治癒形態と言えるものです。.

霊長類モデルからの基礎的エビデンス

ヒトを対象とした画像診断試験が行われるはるか以前に、非ヒト霊長類を用いた基礎研究によって、退縮の生物学的妥当性が確立されていた。これらの研究により、コレステロールを豊富に含む食餌によって動脈硬化を誘導した後、退縮食（低脂肪食）に切り替えると、動脈壁からの顕著な脂質消失、内皮の修復、および病変の構造的安定化が引き起こされることが示された。この初期の動物データは、動脈硬化が不可逆的な終点ではなく、脂質環境の大幅な変化に応答する動的なプロセスであることを裏付けた。.

表1. 非ヒト霊長類における回帰研究

食事介入または薬物療法後の脂質枯渇、内皮修復、および構造的退縮の生物学的メカニズムを示す比較霊長類モデル.

勉強	種	介入	期間	成果
アームストロングら、1970¹³	アカゲザル	動脈硬化惹起食後の低コレステロール食	24ヶ月	脂質の顕著な枯渇と内皮修復
ヴェセリノヴィッチ＆ウィスラー、1976年¹⁴	カニクイザル	コレステロール除去食	生後18ヶ月	細胞壁の脂質喪失とマトリックスの修復
クラークソンら、1981年¹⁵	アカゲザル	リグレッション（低脂肪）食	48ヶ月	内膜肥厚の軽減と病変の安定化
ヘッカーら、2022年¹⁶	カニクイザル	退行食（リグレッション・ダイエット）＋LDL低下療法	12ヶ月	酸化ストレスの低下と血管内皮NOの改善

薬理学的退縮：スタチン、PCSK9阻害薬、オメガ3療法

高強度スタチン

その ASTEROID試験A landmark 2006 serial IVUS study in which rosuvastatin 40 mg daily for 24 months produced statistically significant reductions in both percent atheroma volume and total atheroma volume, providing the first large-scale evidence that intensive statin therapy can regress coronary plaque. 示した ロスバスタチンRosuvastatin, sold as Crestor, is the most potent statin available and stays largely in the liver rather than spreading through the body. 1日40mgに減量 プラーク体積百分率Percent atheroma volume, or PAV, is the share of an artery segment taken up by plaque rather than open channel. (PAV) による 0.98% および 総アテローマ容積Total atheroma volume is an IVUS-derived absolute measure of the total three-dimensional volume of plaque within an imaged coronary segment, reported in cubic millimeters. Unlike PAV, TAV is not normalized to vessel size, so it captures the raw amount of disease removed or added over time. 6.8%による24か月間の¹。その SATURN試験A head-to-head serial IVUS trial comparing rosuvastatin 40 mg with atorvastatin 80 mg over 24 months; both regimens produced coronary plaque regression, confirming that intensive therapy with either high-potency statin achieves similar plaque-volume reductions. これらの知見を2種類の強力なスタチンで確認し、LDL-C低下の程度が退縮の大きさと直接相関することを示した。² 脂質低下作用を超えて、スタチンは 多面発現効果In pharmacology, pleiotropic effects are actions of a drug that go beyond its primary intended mechanism; for incretin therapies, pleiotropic effects include anti-inflammatory activity, endothelial protection, and blood-pressure reduction that are independent of the drugs' primary glucose-lowering and weight-loss actions.減少しました C反応性タンパク質C反応性タンパク（CRP）は、体内のどこかで炎症が起きているときに肝臓が産生する物質です。この検査の高感度バージョンであるhs-CRPは、心疾患のリスクを評価するために使用されます。., 、eNOSカップリングの改善、および酸化ストレスの軽減.³ これらの抗炎症作用は、LDLレベルが控えめな場合でもイベントが抑制される理由を説明するのに役立ちます。.

PCSK9阻害薬

PCSK9PCSK9 is a protein made by your liver that destroys the docking ports your liver uses to pull cholesterol out of your blood. 肝臓のリソソーム分解を促進する LDL受容体LDL受容体は、肝細胞の表面にあるドッキングポートであり、血液中からLDL粒子を捕捉して取り込み、分解する。.. モノクローナル抗体阻害（エボロクマブEvolocumab is an injectable cholesterol medicine in the PCSK9 inhibitor family, usually given every two to four weeks., アリロクマブプラルエントとして販売されているアリロクマブは、PCSK9を阻害する注射用抗体であり、2〜4週間ごとに投与される。.）受容体のリサイクリングを促進し、30 mg/dL未満のLDL-C値をもたらす。 グラゴフGLAGOV added a PCSK9 inhibitor to statin therapy and measured coronary plaque with intravascular ultrasound before and after., エボロクマブとスタチン療法の併用は、スタチン単独療法と比較して、PAVをさらに1%減少させた。⁴ PACMAN-AMIPACMAN-AMI gave a PCSK9 inhibitor to patients immediately after a heart attack and imaged their non-culprit arteries with three different catheter techniques. そして ホイヘンスHUYGENS used optical coherence tomography — a very high-resolution imaging catheter — to see whether a PCSK9 inhibitor changed plaque structure after a heart attack. より厚みが確認された 線維性皮膜The fibrous cap is the tough layer of tissue covering a plaque, separating its greasy core from the bloodstream. そして、より小さな 脂質コアThe lipid core is the soft, greasy center of a plaque, made of cholesterol and the debris of dead immune cells. PCSK9阻害により⁵⁻⁶。これらの組織学的ベネフィットにもかかわらず、平均内腔面積の変化はわずかであり、持続的な閉塞ではなくリモデリングの逆転と一致していた。.

オメガ3脂肪酸（イコサペンタ酸エチル）

EVAPORATE試験において、高用量の イコサペント酸エチルIcosapent ethyl is a purified, high-dose form of the omega-3 fat EPA, sold as Vascepa. 削減された 低吸収プラーク低減衰プラークは、CTスキャンで最も黒く、脂肪分の多いプラークであり、X線が容易に透過するほど柔らかいものです。. 17% 対 プラセボプラセボとは、本物の薬が実際にどのような効果をもたらすかを研究者が知るために投与される、偽の治療法（砂糖の錠剤や生理食塩水の注射など）である。. および線維組織の増加。⁷ EPAはリン脂質膜に組み込まれ、アラキドン酸由来のエイコサノイドを減少させ、炎症を積極的に解消するレゾルビンやプロテクチンを生成する。脂質メディエーターを調節し、内皮のコンプライアンスを改善することで、EPAはスタチン療法を補完し、血管の安定性と血管運動機能の改善の両方をもたらす可能性がある。.

ホールフード・プラントベースのライフスタイルと冠動脈の退縮

ディーン・オーニッシュの研究は今なお基礎的である。 ランセット (1990) および JAMA （1998年）の試験では、低脂肪のホールフード植物性（WFPB）食にストレス管理、運動、 喫煙喫煙は血管の内壁を傷つけ、血圧を上げ、血液を凝固しやすくし、プラークの成長を早めます。. cessation showed a 7.9% angiographic improvement in 狭窄狭窄とは閉塞のことであり、通常は70%の閉塞といったようにパーセンテージで表されます。. at five years without pharmacologic therapy.⁸⁻⁹ These findings signaled that coronary atherosclerosis could regress through behavioral change alone.

Mechanisms of Lifestyle-Driven Regression

• Lipid effects: Eliminating animal fat reduces hepatic LDL output; soluble ファイバー食物繊維は、体内で消化できない植物性食品の部分です。豆類、オーツ麦、野菜、果物、全粒穀物に含まれています。. enhances cholesterol excretion.
• Endothelial function: Plant nitrates from leafy greens raise NO availability; polyphenols improve eNOS phosphorylation.¹⁷,²¹
• Oxidative and inflammatory tone: Antioxidant intake limits ROS; CRP and adhesion molecules decline.²⁰,²²
• Microbiome modulation: Reduced production of trimethylamine N-oxide (TMAOTMAO is a compound your gut bacteria produce from nutrients found in red meat, eggs, and some fish. Higher blood levels have been linked to heart disease.) and increased short-chain fatty acids lower systemic inflammation.
• Metabolic integration: 改善された インスリン感受性インスリン感受性とは、細胞がインスリンに対してどれだけよく反応するかということです。それはインスリン抵抗性の反対です。. and reduced 食後高脂血症Postprandial lipemia is the surge of fat particles in your blood in the hours after eating a meal containing fat. relieve endothelial stress.

Large cohort data (Adventist Health Study-2, EPIC-OxfordA large UK-based prospective cohort that recruited a substantial proportion of vegetarians and vegans, forming part of the broader European Prospective Investigation into Cancer and Nutrition; it reported higher total stroke risk—driven by hemorrhagic stroke—among vegetarians compared with meat-eaters.) confirm lower 虚血性心疾患A condition in which reduced blood supply to the heart muscle, usually from coronary artery atherosclerosis, causes symptoms such as angina or myocardial infarction. incidence among predominantly plant-based populations. Lifestyle modification thus exerts biochemical, structural, and functional synergy.

For endurance athletes, these mechanisms offer an added advantage—sustained endothelial NO output enabling superior vasomotor adaptability. Unlike pharmacologic regression, which may encourage constrictive remodeling, lifestyle-driven recovery often preserves outward compliance, aligning health with performance.

Imaging Evidence and the Nature of Plaque Regression

Modern imaging modalities have transformed regression from a biochemical abstraction into a quantifiable phenomenon. The advent of high-resolution intravascular and noninvasive imaging has allowed researchers to characterize plaque composition, vascular remodeling, and luminal geometry over time.

Intravascular Ultrasound (IVUS)

IVUS has been the cornerstone of regression trials since the 1990s. It enables three-dimensional volumetric assessment of 粉瘤Atheroma is another word for the fatty deposit inside an artery wall — essentially a synonym for plaque, used more often in research writing. burden and vessel wall area. Unlike angiography, which reflects only the lumen, IVUS visualizes the entire arterial wall, revealing compensatory remodeling, lipid pools, and 石灰化石灰化とは、カルシウムがプラークに沈着し、その一部が硬く骨状になることです。.. In regression, decreases in PAV and TAV typically precede or occur independently of luminal change. Virtual histology (VH-IVUS) further distinguishes plaque components, demonstrating that intensive lipid lowering increases fibrous content and reduces 壊死核壊死性コアは、捕捉されたコレステロールを食べてその場で死亡した免疫細胞から形成された、進行したプラークの死滅したドロドロとした中心部である。. volume.

Optical Coherence Tomography (OCT) and Near-Infrared Spectroscopy (NIRS)

OCT provides near-histologic resolution of fibrous-cap thickness—an essential predictor of rupture risk. Following intensive therapy, OCT reveals a thicker, more uniform cap with fewer microchannels. NIRS and NIRS-IVUS hybrid catheters can quantify lipid-core burden index (LCBI)A near-infrared spectroscopy (NIRS) measurement that quantifies the lipid content within a coronary plaque segment; reductions in LCBI under intensive therapy indicate that the plaque's vulnerable, lipid-rich core is shrinking., showing significant decreases under PCSK9 or omega-3 therapy. Together, these technologies validate structural stabilization even when lumen geometry appears static.

Coronary Computed Tomography Angiography (CCTA)

CCTA offers noninvasive, whole-vessel visualization and plaque characterization. In trials such as EVAPORATE, CCTA demonstrated marked regression of low-attenuation, 脂質富化プラーク中心がカルシウムや線維組織ではなくコレステロールエステルや炎症性脂質を主体とするアテローム性動脈硬化性病変。この記事では、このようなプラークは集中的な治療に対して非常に反応性が高く、対角枝分岐部における65パーセントポイントという劇的な退縮は脂質が豊富な病変の改善と一致していると指摘している。. following high-dose EPA.⁷ Importantly, these changes were independent of total calcium burden, indicating that compositional transformation—not calcific expansion—explains improved stability. Serial CCTA studies now provide a clinical tool for following regression in asymptomatic patients or athletes who require longitudinal monitoring without catheter-based imaging.

Magnetic Resonance Imaging (MRI)

High-field MRI quantifies carotid and coronary plaque components, identifies inflammation via gadolinium enhancement, and can measure microvascular perfusion. Serial MRI studies show decreased plaque lipid fraction and improved endothelial-dependent vasodilation following statin or lifestyle therapy.¹²

Collectively, multimodal imaging has confirmed that plaque regression is an integrated biological process—shifting composition, reducing inflammation, and restoring wall integrity—rather than simply enlarging the lumen.

Table 2. Major Human Regression Trials

Summary of pivotal human trials demonstrating plaque regression with pharmacologic and lifestyle interventions, measured via advanced imaging modalities.

勉強	介入	Imaging	Plaque Effect	Lumen Effect
ASTEROID¹	Rosuvastatin 40 mg	IVUS	↓PAV 0.98%, ↓TAV 6.8%	Neutral
SATURN²	Rosuvastatin vs AtorvastatinAtorvastatin, sold as Lipitor, is one of the two strongest statins and among the most prescribed medicines in the world.	IVUS	Regression in both groups	Variable
GLAGOV⁴	Evolocumab + Statin	IVUS	Greater regression	Neutral
EVAPORATE⁷	Icosapent Ethyl + Statin	冠動脈CTアンギオグラフィー	↓Lipid-rich plaque	Neutral
ORNISH⁸⁻⁹	Whole-Food, Plant-Based Lifestyle	QCA	Mild angiographic improvement	Functional gain

The Lumen Paradox and Reverse Remodeling

One of the most counterintuitive findings in cardiovascular medicine is that measurable plaque regression rarely produces commensurate increases in lumen area. This ルーメンのパラドックス originates from the mechanical behavior of arteries under chronic stress.

In the 1987 Glagov study, human autopsies demonstrated 代償性肥大Compensatory enlargement, described by Glagov, is the outward expansion of an artery's wall as plaque accumulates inside it, allowing the channel where blood flows to remain relatively open despite substantial hidden disease; on modern CT imaging, this positive remodeling is considered a high-risk plaque feature associated with lipid-rich, potentially vulnerable plaque rather than evidence of hea… of the 外部弾性膜（EEM）The external elastic membrane is the boundary between an artery's muscular wall and surrounding connective tissue; in intravascular imaging, the area enclosed by the EEM is used to quantify total vessel size including both the open channel and the plaque within the wall. during plaque growth—a mechanism preserving lumen size until approximately 40% of the cross-sectional area is occupied by plaque.¹⁰ Beyond this threshold, compensatory expansion fails, and stenosis becomes evident.

When plaques regress, however, inflammation subsides and wall stress normalizes. The EEM may contract, reversing prior dilation. This 逆リモデリング results in smaller or unchanged luminal areas even though plaque burden decreases and arterial wall composition improves.¹¹ Far from pathological, this constrictive adjustment restores physiologic tension across the media and 外膜外膜は動脈の最も外側の頑丈な層であり、主に結合組織、神経、および血管壁に栄養を供給する微小血管で構成されている。..

Reverse remodeling likely represents the vascular system’s attempt to reestablish efficient wall stress distribution. Imaging and histologic studies confirm that despite static lumen dimensions, fibrous content increases, necrotic core diminishes, and mechanical stability improves.¹²

Implications for Endurance Athletes

For endurance athletes, the paradox raises practical questions. Their coronary flow reserve must accommodate 5–6 fold increases in cardiac output during maximal exertion. Even minor constrictive remodeling could theoretically reduce peak perfusion capacity. Yet, this risk may be mitigated by enhanced endothelial function and 一酸化窒素一酸化窒素は、血管の内壁が血管に弛緩して広がるよう伝えるために産生するガスです。.–mediated vasodilation in athletes, which can expand lumen radius dynamically during exercise. Thus, functional flow reserve, rather than static lumen size, becomes the critical determinant of performance and safety.

Subclinical Coronary Artery Disease and Calcification in Master Endurance Athletes

Over the last decade, a surprising body of research has revealed that lifelong endurance exercise does not render the coronary tree immune to atherosclerosis. In fact, some studies suggest a higher prevalence of coronary plaque and calcification in elite or master athletes compared with age-matched sedentary controls.

The Merghani et al. Study (2017, Circulation)

Merghani and colleagues examined 152 male and female master endurance athletes (mean age 54) and compared them with 92 healthy controls matched for age and 危険因子危険因子とは、高コレステロール粒子、高血圧、喫煙、糖尿病、家族歴など、病気にかかる可能性を高めるものです。..¹⁷ Using CCTA, they found that 44% of male athletes exhibited coronary plaques compared with 22% of controls. Eleven percent of athletes had カルシウムスコアカルシウムスコア（冠動脈カルシウムスコア）とは、CTスキャンから算出される数値であり、冠動脈内の石灰化したプラークの総量を数値化したものです。スコアがゼロの場合は検出可能な石灰化プラークがないことを示し、より高いスコアはプラークの蓄積が多く、心血管疾患のリスクが高いことを反映しています。. greater than 300 アガトストン単位アガトストン単位は、CTスキャンにおける冠動脈カルシウムを定量化するために使用される標準化されたスコアリング単位であり、石灰化病変の密度と面積から算出されます。スコアがゼロの場合は検出可能な石灰化プラークがないことを示し、300以上のスコア（英国マスターズ研究の atleta グループのみに見られた）は高度な石灰化を反映しています。., and 7.5% had luminal stenoses exceeding 50%. Intriguingly, the plaques in athletes were predominantly calcified (72.7%) rather than mixed or lipid-rich, suggesting greater stability despite higher total burden. Furthermore, 14% of male athletes displayed silent myocardial fibrosis on 心臓MRICardiac MRI uses magnetic fields rather than X-rays to image the heart in fine detail, with no radiation.—evidence of prior subclinical ischemic injury.

Confirmatory and Contrasting Studies

These findings were expanded by Aengevaeren et al. (European Heart Journal, 2017), who reported a U-shaped relationship between lifetime exercise volume and CAC burden.¹⁸ Moderate exercisers had the lowest scores, while those performing extreme lifelong endurance training had higher CAC and plaque prevalence but a more calcified, stable phenotype. Baggish and Levine (2017) interpreted these data as an adaptation—exercise may accelerate calcification of existing soft plaquesNon-calcified, lipid-rich atherosclerotic plaque that does not appear bright on a standard calcium score scan but is detectable by CT angiography; it is considered higher risk for rupture than fully calcified plaque., converting them into stable, quiescent structures less likely to rupture.¹⁹

Mechanistic Hypotheses

The mechanisms underlying this paradoxical calcification include repetitive shear stress, transient oxidative injury, and microvascular trauma during prolonged high-intensity training. These stimuli can induce vascular smooth-muscle cell osteogenic transformation, promoting 微小石灰化Microscopic calcium deposits within atherosclerotic plaque that fall below the resolution threshold of conventional CT; unlike dense macrocalcification, microcalcifications can generate mechanical stress within the fibrous cap and increase plaque rupture susceptibility. that later consolidates into dense calcium sheets.

Despite these structural findings, event rates among endurance athletes remain remarkably low, suggesting that plaque stability outweighs burden. Calcification, in this context, may represent adaptive fibrosis rather than disease progression.

Clinical Implications for Screening

These insights reshape preventive cardiology in athletes. Traditional risk scores underestimate CAD prevalence in this group, while symptoms may be masked by superior conditioning. Selective imaging—particularly CAC scoring or CCTA—is appropriate for athletes over 45 with 家族の歴史Family history means whether your close relatives developed heart disease, and how young they were when it happened., 脂質異常症Dyslipidemia is the medical word for an unhealthy pattern of fats in the blood. It can mean high LDL, high triglycerides, low HDL, or some combination., or unexplained performance decline. Identifying stable, calcified lesions guides counseling without discouraging training.

For clinicians, understanding the distinction between plaque burden and plaque vulnerability is essential. A highly calcified lesion may signal a healed or stabilized 動脈動脈は、心臓から全身へ血液を送り出す血管です。., whereas non-calcified, lipid-rich plaques remain the real threat—even in the apparently “fittest” hearts.

Silent Ischemia and Pain Processing in Endurance Athletes

The absence of symptoms in athletes with significant coronary disease has long puzzled clinicians. This “無症候性心筋虚血Silent ischemia is when the heart muscle is starved of oxygen but the person feels nothing at all.” phenomenon is now understood as a consequence of neurobiologic adaptation to chronic exertion and repeated sympathetic activation.

Neurophysiologic Basis

Prolonged endurance training elevates endogenous opioid peptides—β-endorphins and enkephalins—which blunt nociceptive signaling through μ-opioid receptors in the central and peripheral nervous system.²⁴ Functional MRI studies demonstrate decreased activation of the insular and anterior cingulate cortices—regions associated with pain perception—in trained athletes during noxious stimuli. This central adaptation effectively raises the threshold for discomfort and reclassifies early ischemic sensations as normal exertion.

Clinical Evidence

Several cohorts of master athletes have shown electrocardiographic or perfusion evidence of myocardial 虚血虚血とは、組織が要求される働きに対して十分な血液と酸素を得られていない状態のことです。. in the absence of chest pain. Exercise thallium imaging studies from the 1990s first identified this pattern; more recent PET and MRI data confirm ischemia without 狭心症狭心症は、心筋に十分な酸素が供給されていないときに起こる胸の不快感です。圧迫感、締めつけ感、絞られるような感じ、または灼熱感と表現され、腕、首、または顎に広がることがあります。. during maximal workloads. Importantly, some of these athletes exhibit 遅延ガドリニウム造影Late gadolinium enhancement (LGE) is a cardiac MRI technique in which a contrast agent accumulates in areas of scarred or fibrotic myocardium and appears bright on delayed imaging, indicating previous microscopic or clinical cardiac injury; 12–14% of masters athletes in the studies described showed this pattern, sometimes without any prior diagnosed heart attack. consistent with silent myocardial fibrosis—“healed” infarcts unrecognized during life.¹⁷

Implications for Clinical Assessment

Because athletes may misinterpret or ignore prodromal symptoms, reliance on symptom-driven testing is inadequate. Cardiologists should consider baseline CAC or CCTA screening in athletes over 45 years old, particularly those with familial dyslipidemia or long training histories. Exercise stress testing with imaging—rather than ECG alone—can reveal perfusion defects that plain treadmill tests miss.²³ Recognition of silent ischemia is crucial to prevent sudden 心臓発作心血管系を対象とした臨床試験において、心筋梗塞、不安定狭心症、心臓死などの臨床的に重要な心血管関連事象を評価項目として使用する。. during competition.

Hemodynamic Principles: Why Millimeters Matter

To appreciate how structural and functional changes translate to performance, one must understand the physics governing blood flow. Coronary blood flow follows Poiseuille’s law, which states:

$$Q = \frac{\pi \cdot \Delta P \cdot r^4}{8 \cdot \mu \cdot L}$$

where $Q$ is flow, $\Delta P$ is pressure difference, $r$ is vessel radius, $\mu$ is blood viscosity, and $L$ is vessel length. Flow thus increases with the fourth power of radius.

Physiologic Consequences

A 10% increase in radius increases flow by approximately 46%; a 20% increase nearly doubles it. Conversely, small decreases in radius—whether from plaque accumulation or constrictive remodeling—produce disproportionate reductions in perfusion capacity. For endurance athletes whose cardiac output may reach 30 L/min, these geometric nuances determine the ceiling of aerobic performance.

Dynamic Vasomotion

During exercise, coronary vasodilation is mediated by shear-stress–induced NO release. Healthy 内皮内皮は、すべての血管の内側にある極めて薄く滑らかな裏地であり、厚さはわずか1細胞分です。. expands epicardial vessels and dilates arterioles to match myocardial oxygen demand. When 内皮機能障害血管内皮機能障害とは、その薄い内側の裏打ちが十分に機能しなくなる状態です。血管が適切に拡張せず、バリア機能がより漏れやすくなります。. coexists with plaque, this dilation reserve is blunted. Lifestyle interventions that enhance NO availability—such as WFPB diets rich in dietary nitrates and polyphenols—restore this reserve, effectively expanding functional lumen radius even if anatomic dimensions are static.

Integration with Regression

Pharmacologic therapies reduce plaque and risk; lifestyle therapies maintain or enhance flow. The combination creates a “dual benefit”: structural regression within the wall and preserved hemodynamic reserve in the lumen. This synergy underpins the thesis that optimal care of the endurance athlete requires both medical and nutritional precision.

Clinical Implications and Author Perspective

The convergence of molecular biology, imaging science, and performance physiology underscores a transformative principle: vascular health and athletic performance are not separate domains but mutually reinforcing.

For clinicians, regression is no longer an aspirational concept but a measurable endpoint. Percent atheroma volume, plaque composition, and cap thickness have replaced crude angiographic narrowing as markers of success. Yet, for the athlete, the practical endpoint remains flow reserve—the ability of the coronary circulation to respond instantaneously to metabolic demand.

Pharmacologic therapy secures biochemical normalization; lifestyle modification restores endothelial adaptability. The challenge is to personalize interventions such that structural regression does not come at the expense of vasomotor responsiveness.

It is within this framework that Dr. Peter Megdal’s personal experience becomes instructive.

Author Reflection: The N + 1 Story — Healing, Adaptation, and Performance

Dr. Peter Megdal, a lifelong endurance athlete and scientist, exemplifies the dual pursuit of vascular healing and human performance. In his early fifties, despite holding several age-group world records in ultra-endurance events, he was unexpectedly found to have subclinical coronary atherosclerosis during imaging performed for research. The discovery was paradoxical: how could someone with exceptional aerobic capacity harbor measurable plaque?

Rather than view this as defeat, Dr. Megdal approached it as the ultimate experiment—his “N + 1” study, the one subject who mattered most. Drawing on decades of biochemical expertise, he implemented a rigorous combination of intensive lipid lowering, whole-food plant-based nutrition, and structured endurance training designed around recovery and endothelial optimization.

Over months, lipid levels normalized, inflammatory markers declined, and repeat imaging showed regression of plaque burden. Endothelial function, assessed by flow-mediated dilation, improved dramatically. Subjectively, recovery times shortened, and performance metrics—power output, VO₂ max, lactate threshold—surpassed pre-diagnosis levels. Within two years, he returned to elite competition and established new age-group world records, a living demonstration that arterial healing and peak human function can coexist.

Dr. Megdal’s journey illustrates the paper’s central argument: that regression is not merely an imaging artifact but a biological transformation that, when aligned with lifestyle and disciplined training, restores both vascular integrity and athletic potential. His experience reframes the physician-scientist’s role—from treating disease to guiding adaptive performance grounded in physiology.

Future Directions

1. Beyond LDL: Molecular and Functional Targets

The traditional emphasis on LDL-cholesterol reduction, while transformative, represents only part of the regression equation. Future therapies will increasingly target residual inflammatory and oxidative pathways. Agents modulating interleukin-1β (e.g., カナキヌマブCanakinumab is a monoclonal antibody that targets interleukin-1β (IL-1β), a key inflammatory signaling protein; it was the active drug in the CANTOS trial, where it reduced cardiovascular events without affecting LDL cholesterol.) or リポ蛋白(a)リポタンパク(a)（Lp(a)と表記され、「L-P-リトル-a」と発音される）は、余分な粘着性のあるタンパク質が付着したLDL様粒子です。. hold promise for individuals with low LDL yet persistent plaque activity. For athletes, whose oxidative flux is naturally elevated, therapies that temper reactive oxygen species without blunting mitochondrial adaptation may optimize both vascular and muscular recovery.

Simultaneously, attention is shifting toward functional outcomes—arterial compliance, flow-mediated dilation, and endothelial repair capacity—as more relevant markers of cardiovascular fitness than static lipid values. Integration of these physiologic metrics into athletic screening may redefine how cardiometabolic performance is measured.

2. Advanced Imaging and Computational Hemodynamics

Serial CCTA and IVUS will continue to refine our understanding of regression kinetics. Next-generation photon-counting CT and ultra-high-resolution MRI promise to detect microcalcification, cap thickness, and 新生血管形成Neovascularization is the growth of new blood vessels. Inside a plaque, they sprout from the vessels feeding the artery's own wall. with unprecedented clarity. When paired with computational fluid dynamics, these images can model shear stress distribution, predicting which plaques will regress or stabilize under various interventions.

For athletes, such modeling could reveal how training intensity, heart rate variabilityHeart rate variability (HRV) is the natural beat-to-beat variation in the time between heartbeats, and is used as a non-invasive measure of autonomic nervous system balance — higher variability generally reflecting greater parasympathetic (rest-and-digest) activity. It is listed in the article as one of the outcomes measured in meditation trials., and coronary flow patterns interact with plaque biology—a fusion of engineering and medicine that may personalize training prescriptions to minimize vascular stress.

3. Lifestyle–Pharmacologic Synergy

Emerging evidence supports a hybrid model: pharmacologic LDL-C suppression combined with whole-food, plant-based nutrition to sustain endothelial tone and systemic 代謝の健康Metabolic health describes how well your body handles blood sugar, blood pressure, fats, and body fat storage.. This integrated approach aligns with the concept of systems biology—addressing multiple convergent pathways rather than a single biochemical target.

Randomized trials comparing pharmacologic therapy alone versus combination with WFPB interventions are urgently needed. Endpoints should extend beyond plaque regression to include arterial elasticity, flow reserve, and athletic performance metrics. Such studies could redefine cardiovascular prevention as a continuum between disease management and physiologic optimization.

4. Exercise Physiology and Adaptive Remodeling

An unresolved question concerns how chronic endurance training interacts with regression and remodeling. Is the increased calcification seen in lifelong athletes a benign stabilization process or an adaptive trade-off? Understanding the cellular signals that drive osteogenic transformation in vascular smooth muscle could reveal ways to preserve arterial flexibility without compromising stability.

Future research should distinguish between beneficial physiologic remodeling and maladaptive calcification, possibly through longitudinal cohorts combining high-resolution imaging with molecular バイオマーカーバイオマーカーとは、健康や病気の状態について教えてくれる、体内で測定可能なもののことであり、例えば、検査値、スキャン画像の結果、血圧の数値などが挙げられます。. of bone–vascular crosstalk (e.g., osteoprotegerin, BMP-2).

5. Precision Prevention in Athletic Cardiology

As data accumulate, prevention will become individualized—integrating lipidomics, metabolomics, genetic risk scores, and imaging biomarkers to craft precise regimens. Machine-learning models may soon predict who among master athletes is most likely to develop subclinical CAD despite fitness, and who will benefit most from aggressive lipid lowering versus lifestyle modification alone.

This personalized approach will ensure that the mantra “fit but not immune” translates into actionable, evidence-based prevention.

結論

Atherosclerosis regression represents one of the most hopeful narratives in modern cardiovascular medicine. It is not merely the 反転REVERSAL compared moderate and intensive statin therapy, using intravascular ultrasound to measure what happened to coronary plaque. of a pathological process but the reawakening of the vessel’s innate capacity for repair. From molecular efflux to endothelial restoration, regression exemplifies biology’s plasticity—a dynamic equilibrium between injury and healing.

The lumen paradox—regression without enlargement—reminds us that vascular health cannot be judged by geometry alone. Stability, composition, and functional responsiveness are equally vital. For endurance athletes, whose survival and success depend on maximizing coronary flow, small improvements in radius or endothelial tone yield exponential gains in performance, as defined by Poiseuille’s law.

Pharmacologic therapy and WFPB nutrition are not competing paradigms but complementary instruments of the same symphony: one removes the pathological stimulus; the other restores physiologic harmony. Together they promote a vessel that is not only structurally sound but dynamically alive.

Dr. Peter Megdal’s “N + 1 Story” embodies this synthesis. His journey from the discovery of 無症候性動脈硬化症Subclinical atherosclerosis means plaque is present but has not yet caused any symptoms or events. to documented regression and renewed world-record performance symbolizes the translation of scientific knowledge into human transformation. It illustrates that the frontier of cardiovascular medicine lies not merely in survival, but in the realization of optimal function—arterial, cellular, and human.

Acknowledgment

The author reports no conflicts of interest.

参考文献

1. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556-1565. doi:10.1001/jama.295.13.jpc60002
2. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078-2087. doi:10.1056/NEJMoa1110874
3. Rivera FB, Cha SW, Varona MC, et al. Atherosclerotic coronary plaque regression from lipid-lowering therapies: A meta-analysis and meta-regression. Am J Prev Cardiol. 2024;18:100645. Published 2024 Mar 11. doi:10.1016/j.ajpc.2024.100645
4. Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016;316(22):2373-2384. doi:10.1001/jama.2016.16951
5. Räber L, Ueki Y, Otsuka T, et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA. 2022;327(18):1771-1781. doi:10.1001/jama.2022.5218
6. Oyama K, Furtado RHM, Fagundes A Jr, et al. Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization. J Am Coll Cardiol. 2021;77(3):259-267. doi:10.1016/j.jacc.2020.11.011
7. Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020;41(40):3925-3932. doi:10.1093/eurheartj/ehaa652
8. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 1990;336(8708):129-133. doi:10.1016/0140-6736(90)91656-u
9. Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998;280(23):2001-2007. doi:10.1001/jama.280.23.2001
10. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316(22):1371-1375. doi:10.1056/NEJM198705283162204
11. Tsujita K, Sugiyama S, Sumida H, et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS Trial): Study protocol for a randomized controlled trial. J Cardiol. 2015;66(4):353-358. doi:10.1016/j.jjcc.2014.12.011
12. Yuan C, Kerwin WS, Yarnykh VL, et al. MRI of atherosclerosis in clinical trials. NMR Biomed. 2006;19(6):636-654. doi:10.1002/nbm.1065
13. Armstrong ML, Warner ED, Connor WE. Regression of coronary atheromatosis in rhesus monkeys. Circ Res. 1970;27(1):59-67. doi:10.1161/01.res.27.1.59
14. Weingand KW. Atherosclerosis research in cynomolgus monkeys (Macaca fascicularis). Exp Mol Pathol. 1989;50(1):1-15. doi:10.1016/0014-4800(89)90052-x
15. Yamada T, Yoshikuni Y, Taira M, et al. Diet-induced atherosclerosis in cynomolgus monkey aorta and regression by the sixth-month observation. Angiology. 1992;43(12):1008-1019. doi:10.1177/000331979204301207
16. Hecker M, Moser M, Schmoldt H, et al. Regression of atherosclerosis with LDL lowering and oxidative stress reduction in primates. Sci Rep. 2022;12(1):4589.
17. Merghani A, Maestrini V, Rosmini S, et al. Prevalence of Subclinical Coronary Artery Disease in Masters Endurance Athletes With a Low Atherosclerotic Risk Profile. Circulation. 2017;136(2):126-137. doi:10.1161/CIRCULATIONAHA.116.026964
18. Aengevaeren VL, Mosterd A, Braber TL, et al. Relationship Between Lifelong Exercise Volume and Coronary Atherosclerosis in Athletes. Circulation. 2017;136(2):138-148. doi:10.1161/CIRCULATIONAHA.117.027834
19. Baggish AL, Levine BD. Coronary Artery Calcification Among Endurance Athletes: “Hearts of Stone”. Circulation. 2017;136(2):149-151. doi:10.1161/CIRCULATIONAHA.117.028750
20. Esposito K, Marfella R, Ciotola M, et al. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA. 2004;292(12):1440-1446. doi:10.1001/jama.292.12.1440
21. Mathur R, Ahmid Z, Ashor AW, Shannon O, Stephan BCM, Siervo M. Effects of dietary-based weight loss interventions on biomarkers of endothelial function: a systematic review and meta-analysis. Eur J Clin Nutr. 2023;77(10):927-940. doi:10.1038/s41430-023-01307-6
22. Dod HS, Bhardwaj R, Sajja V, et al. Effect of intensive lifestyle changes on endothelial function and on inflammatory markers of atherosclerosis. Am J Cardiol. 2010;105(3):362-367. doi:10.1016/j.amjcard.2009.09.038
23. Sharma S, Merghani A, Mont L. Exercise and the heart: the good, the bad, and the ugly. Eur Heart J. 2015;36(23):1445-1453. doi:10.1093/eurheartj/ehv090
24. Thornton C, Baird A, Sheffield D. Athletes and Experimental Pain: A Systematic Review and Meta-Analysis. J Pain. 2024;25(6):104450. doi:10.1016/j.jpain.2023.12.007